Novartis wins U.S. approval for targeted cancer drug combination
FRANKFURT (Reuters) – A targeted oral drug combination by Novartis won U.S. approval for use in a wide range of advanced solid tumours that are driven by a certain genetic contributor, widening the use of a novel treatment approach that is known as tumour agnostic. The Food and Drug Administration early on Thursday granted accelerated …
Novartis wins U.S. approval for targeted cancer drug combination Read More »









